Article
Cardiac & Cardiovascular Systems
Kirsty McDowell, Ross Campbell, Joanne Simpson, Jonathan W. Cunningham, Akshay S. Desai, Pardeep S. Jhund, Martin P. Lefkowitz, Jean L. Rouleau, Karl Swedberg, Michael R. Zile, Scott D. Solomon, Milton Packer, John J. V. McMurray
Summary: This study investigated the improvement in risk prediction of heart failure by adding candidate biomarkers to comprehensive models with routinely collected clinical and laboratory variables. Four biomarkers (hs-TnT, GDF-15, cystatin C, and TIMP-1) were independently associated with all outcomes. However, only hs-TnT remained an independent predictor of the three endpoints when all biomarkers were added simultaneously to the PREDICT-HF model. Individually or in combination, the other biomarkers did not significantly improve discrimination or reclassification of prediction.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Medicine, General & Internal
Lukasz Wolowiec, Joanna Banach, Jacek Budzynski, Anna Wolowiec, Mariusz Kozakiewicz, Maciej Bielinski, Albert Jasniak, Agata Olejarczyk, Grzegorz Grzesk
Summary: The study aimed to assess the prognostic value of plasma catestatin concentration in patients with heart failure with reduced ejection fraction (HFrEF) in predicting unplanned hospitalization and all-cause death at a 2-year follow-up. The study included 122 hospitalized Caucasian patients in NYHA classes II to IV. Patients who died during the follow-up period had higher levels of CST, NT-proBNP, troponin T, creatinine, and glucose, and lower TAPSE, hemoglobin concentration, hematocrit, and platelet count compared to survivors. Plasma catestatin concentration was positively associated with NYHA class and blood NT-proBNP concentration. Higher plasma catestatin concentration increased the risk of all-cause death by more than five times. Plasma CST concentration is a valuable prognostic parameter in predicting death from all causes and unplanned hospitalization in patients with HFrEF.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, General & Internal
Juan Martinez-Milla, Alvaro Acena, Ana Pello, Marta Lopez-Castillo, Hans Paul Gaebelt, Oscar Gonzalez-Lorenzo, Nieves Tarin, Carmen Cristobal, Luis M. Blanco-Colio, Jose Luis Martin-Ventura, Ana Huelmos, Andrea Kallmeyer, Joaquin Alonso, Carlos Gutierrez-Landaluce, Lorenzo Lopez Bescos, Jesus Egido, Ignacio Mahillo-Fernandez, Oscar Lorenzo, Maria Luisa Gonzalez-Casaus, Jose Tunon
Summary: This study aims to assess the influence of NT-ProBNP on the prognostic role of MM markers in patients with stable coronary artery disease. It found that PTH and NT-ProBNP are predictors of poor outcome in patients with NT-ProBNP > 125 pg/mL, while calcidiol and non-HDL cholesterol are the independent predictors of poor outcome in the subgroup of patients with NT-ProBNP <= 125 pg/mL.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Physiology
Alba Maestro-Benedicto, Mercedes Rivas-Lasarte, Juan Fernandez-Martinez, Laura Lopez-Lopez, Eduard Sole-Gonzalez, Vicens Brossa, Sonia Mirabet, Eulalia Roig, Juan Cinca, Jesus Alvarez-Garcia, Alessandro Sionis
Summary: Adding lung ultrasound (LUS) evaluation at discharge can improve the predictive value of most contemporary heart failure (HF) risk scores.
FRONTIERS IN PHYSIOLOGY
(2022)
Article
Infectious Diseases
Rosa Zampino, Domenico Iossa, Maria Paola Ursi, Lorenzo Bertolino, Roberto Andini, Rosa Molaro, Oriana Fabrazzo, Silvia Leonardi, Luigi Atripaldi, Emanuele Durante-Mangoni
Summary: The levels of pro-ADM and copeptin in IE are associated with older age and prior chronic kidney disease. Pro-ADM can predict hospital mortality risk, copeptin can predict 1-year mortality risk, and a high PCT value is linked to Staphylococcus aureus etiology.
BMC INFECTIOUS DISEASES
(2021)
Article
Medical Laboratory Technology
Helge Rosjo, Jennifer Meessen, Anett Hellebo Ottesen, Roberto Latini, Torbjorn Omland, on behalf of the GISSI-HF Investigators GISSI-HF Investigators
Summary: This study aimed to assess whether circulating secretoneurin (SN) concentrations could provide prognostic information in patients with chronic heart failure (HF). Plasma SN concentrations were measured in a large multicenter trial, and higher concentrations were found to be associated with mortality in chronic HF patients. Therefore, plasma SN concentrations can serve as a prognostic marker in patients with chronic HF.
CLINICAL BIOCHEMISTRY
(2023)
Article
Cardiac & Cardiovascular Systems
M. M. Schreuder, A. Schuurman, K. M. Akkerhuis, A. A. Constantinescu, K. Caliskan, J. van Ramshorst, T. Germans, V. A. Umans, E. Boersma, J. E. Roeters van Lennep, I. Kardys
Summary: The study found that female patients with HFrEF have higher risk in biomarkers such as NT-proBNP, HsTnT, and CRP, but show no significant differences compared to males in renal function markers.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2021)
Article
Immunology
Xu Zhu, Iokfai Cheang, Fang Xu, Rongrong Gao, Shengen Liao, Wenming Yao, Yanli Zhou, Haifeng Zhang, Xinli Li
Summary: This study assessed the long-term prognostic value of combining accessible inflammatory markers in relation to all-cause mortality in patients with acute heart failure (AHF). The results showed that inflammatory biomarkers were associated with the risk of all-cause mortality in AHF patients, and the inflammatory prognostic scoring (IPS) system significantly improved the predictive power of the model and could be used as a practical tool for individualized risk stratification of AHF patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, General & Internal
Edoardo Sciatti, Anna Merlo, Claudio Scangiuzzi, Raul Limonta, Mauro Gori, Emilia D'Elia, Alberto Aimo, Giuseppe Vergaro, Michele Emdin, Michele Senni
Summary: In recent years, there has been a growing interest in using multiple biomarkers, such as soluble suppression of tumorigenicity-2 (sST2), to stratify the risk and identify pathophysiological processes associated with heart failure. sST2 is produced in response to myocardial stress and is associated with both cardiac and immune cells. This article aims to review the prognostic value of sST2 in chronic and acute heart failure and provides a flowchart for its potential use in clinical practice.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Yan Gao, Xueke Bai, Jiapeng Lu, Lihua Zhang, Xiaofang Yan, Xinghe Huang, Hao Dai, Yanping Wang, Libo Hou, Siming Wang, Aoxi Tian, Jing Li
Summary: By analyzing 18 biomarkers and clinical indicators, and utilizing support vector machine (SVM) for prediction modeling, the study showed an effective improvement in risk prediction for patients with heart failure with preserved ejection fraction (HFpEF).
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Danielle J. Beetler, Katelyn A. Bruno, Damian N. Di Florio, Erika J. Douglass, Swikriti Shrestha, Carsten Tschoepe, Madeleine W. Cunningham, Jan Krejci, Julie Bienertova-Vasku, Sabine Pankuweit, Dennis M. McNamara, Eun-Seok Jeon, Sophie van Linthout, Lori A. Blauwet, Leslie T. Cooper, DeLisa Fairweather
Summary: This study aimed to investigate the sex and age differences in soluble ST2 (sST2) levels for various cardiovascular diseases (CVDs). Using ELISA kit, sST2 levels were measured in patients with myocarditis, cardiomyopathy, coronary artery disease (CAD), myocardial infarct (MI), and congestive heart failure (CHF) and compared to controls without CVDs. The results showed that myocarditis occurred in younger patients around the age of 40, while other CVDs were more common in individuals around the age of 60. There were significant differences in sST2 levels between sexes in myocarditis and cardiomyopathy, but not in other CVDs.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Elvira Delcuratolo, Alberto Palazzuoli, Francesca Coppi, Anna Vittoria Mattioli, Paolo Severino, Francesco Tramonte, Francesco Fedele
Summary: Patients with heart failure are conventionally stratified based on their ejection fraction and gender, as there may be significant differences in the onset, development, and clinical course of the disease between males and females. Despite these differences, treatment for heart failure is similar across the whole population.
Review
Cardiac & Cardiovascular Systems
Paola Gargiulo, Federica Marzano, Marco Salvatore, Christian Basile, Davide Buonocore, Antonio Luca Maria Parlati, Ermanno Nardi, Gaetano Asile, Vincenza Abbate, Angela Colella, Alfonsina Chirico, Caterina Marciano, Stefania Paolillo, Pasquale Perrone-Filardi
Summary: Heart failure is a significant health issue with a high burden on both society and the economy. Recent research has shown that microRNAs play an important role in the development and prognosis of heart failure, serving as biomarkers for diagnosis and prognosis. Exploration of microRNAs as potential therapeutic targets is also ongoing.
Article
Cardiac & Cardiovascular Systems
Daichi Maeda, Yumiko Kanzaki, Kazushi Sakane, Kosuke Tsuda, Kanako Akamatsu, Ryoto Hourai, Takahiro Okuno, Daisuke Tokura, Sayuri Nakayama, Hitomi Hasegawa, Hideaki Morita, Takahide Ito, Masaaki Hoshiga
Summary: This study compared the prognostic value of FIB-4 and FIB-5 in patients with heart failure. The results showed that FIB-5 had better predictive value for prognosis in heart failure patients than FIB-4.
Article
Cardiac & Cardiovascular Systems
Roberta Florido, Lucia Kwak, Justin B. Echouffo-Tcheugui, Sui Zhang, Erin D. Michos, Vijay Nambi, Ronald B. Goldberg, Ron C. Hoogeveen, Mariana Lazo, Gary Gerstenblith, Wendy S. Post, Roger S. Blumenthal, Josef Coresh, Aaron R. Folsom, Elizabeth Selvin, Christie Ballantyne, Chiadi E. Ndumele
Summary: This study found a strong association between obesity and galectin-3, a biomarker of cardiac inflammation and fibrosis. The combination of obesity and elevated galectin-3 is associated with a significantly increased risk of heart failure.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Review
Cardiac & Cardiovascular Systems
Frank Lezoualc'h, Lina Badimon, Hana Baker, Monique Bernard, Gabor Czibik, Rudolf A. de Boer, Thomas D'Humieres, Micheline Kergoat, Mark Kowala, Jennifer Rieusset, Gemma Vilahur, Maximin Detrait, Chris Watson, Genevieve A. Derumeaux
Summary: Diabetic cardiomyopathy is a distinct, multifactorial disease that leads to ventricular hypertrophy and abnormal myocardial contractility. Animal models provide opportunities to study its mechanisms, but there are limitations when extrapolating findings to humans.
CARDIOVASCULAR RESEARCH
(2023)
Article
Cardiac & Cardiovascular Systems
Toru Kondo, Karola S. Jering, C. Jan Willem Borleffs, Rudolf A. de Boer, Brian L. Claggett, Akshay S. Desai, Dan Dobreanu, Silvio E. Inzucchi, Adrian F. Hernandez, Stefan P. Janssens, Pardeep S. Jhund, Mikhail N. Kosiborod, Carolyn S. P. Lam, Anna Maria Langkilde, Felipe A. Martinez, Magnus Petersson, Pham Nguyen Vinh, Muthiah Vaduganathan, Scott D. Solomon, John J. V. McMurray
Summary: This study investigated how patient characteristics and outcomes vary according to the duration of heart failure, and compared the efficacy and safety of dapagliflozin in different stages of heart failure. The results showed that patients with longer-duration heart failure were older, had more comorbidities, and experienced worse symptoms. Dapagliflozin had consistent benefits across different stages of heart failure.
Article
Cardiac & Cardiovascular Systems
S. Abou Kamar, Y. S. Aga, M. de Bakker, V. J. van den Berg, M. Strachinaru, D. Bowen, R. Frowijn, K. M. Akkerhuis, J. J. Brugts, O. Manintveld, V. Umans, M. Geleijnse, R. A. de Boer, E. Boersma, I. Kardys, B. M. van Dalen
Summary: This study investigated the prognostic value of repeated measurements of left atrial reservoir strain (LASr) in heart failure patients. The results showed that both baseline and repeated measurements of LASr were significantly associated with adverse events, independent of other echo parameters and NT-proBNP. However, temporal trajectories of LASr did not provide additional prognostic value compared to single measurements of LASr.
CLINICAL RESEARCH IN CARDIOLOGY
(2023)
Article
Medicine, General & Internal
Jasper J. Brugts, Sumant P. Radhoe, Pascal R. D. Clephas, Dilan Aydin, Marco W. F. van Gent, Mariusz K. Szymanski, Michiel Rienstra, Mieke H. van den Heuvel, Carlos A. da Fonseca, Gerard C. M. Linssen, C. Jan Willem Borleffs, Eric Boersma, Folkert W. Asselbergs, Arend Mosterd, Hans-Peter Brunner-La Rocca, Rudolf A. de Boer
Summary: The MONITOR-HF trial conducted in the Netherlands examined the impact of haemodynamic monitoring on quality of life and heart failure hospitalization in patients with heart failure. The study found that haemodynamic monitoring significantly improved patients' quality of life and reduced heart failure hospitalizations.
Article
Medicine, General & Internal
Navin Suthahar, Dongyu Wang, Joseph Pierre Aboumsallem, Canxia Shi, Sanne de Wit, Elizabeth E. Liu, Emily S. Lau, Stephan J. L. Bakker, Ron. T. Gansevoort, Bert van der Vegt, Manol Jovani, Bernard E. Kreger, Greta Lee Splansky, Emelia J. Benjamin, Ramachandran S. Vasan, Martin G. Larson, Daniel Levy, Jennifer E. Ho, Rudolf A. de Boer
Summary: This study evaluated the value of serial CRP measurements in predicting the risk of CVD, cancer, and mortality. The results showed that both baseline CRP levels and subsequent increases in CRP were associated with future CVD, cancer, and mortality.
MAYO CLINIC PROCEEDINGS
(2023)
Article
Cardiac & Cardiovascular Systems
Jawad H. Butt, Kieran F. Docherty, Brian L. Claggett, Akshay S. Desai, Magnus Petersson, Anna Maria Langkilde, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Lars Kober, Carolyn S. P. Lam, Felipe A. Martinez, Piotr Ponikowski, Marc S. Sabatine, Sanjiv J. Shah, Muthiah Vaduganathan, Pardeep S. Jhund, Scott D. Solomon, John J. V. McMurray
Summary: This study found that gout is common in patients with heart failure and sodium-glucose cotransporter 2 inhibitors can reduce uric acid levels. Gout was associated with worse clinical outcomes, but the efficacy of dapagliflozin was consistent in patients with and without gout. Dapagliflozin also reduced the initiation of new treatments for hyperuricemia and gout.
Article
Cardiac & Cardiovascular Systems
Alexander Peikert, Alvin Chandra, Mikhail N. Kosiborod, Brian L. Claggett, Akshay S. Desai, Pardeep S. Jhund, Carolyn S. P. Lam, Silvio E. Inzucchi, Felipe A. Martinez, Rudolf A. de Boer, Adrian F. Hernandez, Sanjiv J. Shah, Stefan P. Janssens, Jan Belohlavek, C. Jan Willem Borleffs, Dan Dobreanu, Anna Maria Langkilde, Olof Bengtsson, Magnus Petersson, John J. V. McMurray, Scott D. Solomon, Muthiah Vaduganathan
Summary: In this study, dapagliflozin was found to improve the overall health status of heart failure patients. The improvements were particularly significant in domains related to symptom frequency and physical limitations, which are more easily recognized and communicated to patients.
Article
Cardiac & Cardiovascular Systems
Pardeep S. Jhund, Brian L. Claggett, Atefeh Talebi, Jawad H. Butt, Samvel B. Gasparyan, Lee-Jen Wei, Zachary R. McCaw, Ulrica Wilderaeng, Olof Bengtsson, Akshay S. Desai, Magnus Petersson, Anna Maria Langkilde, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Carolyn S. P. Lam, Felipe A. Martinez, Sanjiv J. Shah, Muthiah Vaduganathan, Scott D. Solomon, John J. V. McMurray
Summary: In the DELIVER trial, dapagliflozin reduced the risk of first worsening heart failure event or cardiovascular death in patients with heart failure. This study aimed to evaluate the effect of dapagliflozin on total heart failure events and cardiovascular death. The results showed that dapagliflozin reduced the rate of total heart failure events and cardiovascular death regardless of left ventricular ejection fraction (EF).
Article
Cardiac & Cardiovascular Systems
Shingo Matsumoto, Toru Kondo, Mingming Yang, Ross T. Campbell, Kieran F. Docherty, Rudolf A. de Boer, Akshay S. Desai, Carolyn S. P. Lam, Milton Packer, Bertram Pitt, Jean L. Rouleau, Muthiah Vaduganathan, Faiez Zannad, Michael R. Zile, Scott D. Solomon, Pardeep S. Jhund, John J. V. McMurray
Summary: This study investigated the association between the use of calcium channel blockers (CCBs) and clinical outcomes in patients with heart failure (HF) and found that CCB use was not significantly associated with worse outcomes in HF patients.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Saha Chatur, Muthiah Vaduganathan, Brian L. Claggett, Finnian R. Mc Causland, Akshay S. Desai, Pardeep S. Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Carolyn S. P. Lam, Felipe A. Martinez, Sanjiv J. Shah, Marc S. Sabatine, Lars Kober, Piotr Ponikowski, Bela Merkely, Magnus Petersson, Anna Maria Langkilde, John J. V. McMurray, Scott D. Solomon
Summary: This study aimed to investigate the safety and efficacy of continuing SGLT2 inhibitors in heart failure (HF) patients with a decline in estimated glomerular filtration rate (eGFR) below a certain threshold. The study found that patients with eGFR decline to <25 mL/min/1.73 m(2) had a higher risk of cardiovascular adverse events, but continuation of dapagliflozin treatment had no excess in safety outcomes and showed benefits in these patients.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Jishnu Malgie, Pascal R. D. Clephas, Hans-Peter Brunner-La Rocca, Rudolf A. de Boer, Jasper J. Brugts
Summary: Multiple landmark trials in the past decade have significantly advanced the treatment of heart failure with reduced ejection fraction (HFrEF). The introduction of four main drug classes, including angiotensin-receptor neprilysin inhibitors/angiotensin-converting-enzyme inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors, into the latest ESC guideline has proven their life-saving effect. Rapid drug implementation and up-titration have been shown to be superior to the traditional step-by-step approach, and various strategies have been proposed to reduce the time needed for the titration process.
HEART FAILURE REVIEWS
(2023)
Review
Oncology
Canxia Shi, Sanne de Wit, Emina Ucambarlic, George Markousis-Mavrogenis, Elles M. Screever, Wouter C. Meijers, Rudolf A. de Boer, Joseph Pierre Aboumsallem
Summary: Multifactorial diseases are caused by a combination of genetic and environmental factors and impose a considerable healthcare burden. This review summarizes the evidence regarding the relationship between multifactorial diseases and cancer, aiming to increase clinicians' awareness. The frequency of cancer is increasing dramatically among the aging population, and there is a growing awareness of the connection between cancer and multifactorial diseases.
Meeting Abstract
Cardiac & Cardiovascular Systems
Safia Chatur, M. Vaduganathan, B. Claggett, A. S. Desai, P. S. Jhund, R. A. De Boer, A. F. Hernandez, S. E. Inzucchi, M. N. Kosiborod, C. S. P. Lam, F. Martinez, S. J. Shah, A. M. Langkilde, J. J. V. Mc Murray, S. D. Solomon
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Meeting Abstract
Cardiac & Cardiovascular Systems
J. Jieling Chen, D. Booth, J. A. Davis, P. Mcewan, R. A. De Boer, J. Comin-Colet, S. D. Solomon, E. Bachus, J. J. V. Mcmurray
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Meeting Abstract
Cardiac & Cardiovascular Systems
B. Mahmoud, R. De Brouwer, D. W. D. Kuster, J. Van der Velden, D. J. Van Veldhuisen, R. A. De Boer, B. D. Westenbrink
EUROPEAN JOURNAL OF HEART FAILURE
(2023)